Ken Herrmann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7019186/publications.pdf

Version: 2024-02-01

216 papers	10,648 citations	44069 48 h-index	40979 93 g-index
220 all docs	220 docs citations	220 times ranked	7809 citing authors

#	Article	IF	Citations
1	Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision: a phantom study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2023, 67, .	0.7	8
2	Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET: Myth or Reality?. Journal of Nuclear Medicine, 2022, 63, 226-232.	5.0	42
3	18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Journal of Nuclear Medicine, 2022, 63, 199-204.	5.0	3
4	COVID-19 Pandemic: What Have We Learned and What to Expect in the Future?. Seminars in Nuclear Medicine, 2022, 52, 86-89.	4.6	2
5	Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma. Journal of Nuclear Medicine, 2022, 63, 396-398.	5.0	18
6	Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. Endocrine, 2022, 75, 293-302.	2.3	8
7	Comparison of nodal staging between CT, MRI, and [18F]-FDG PET/MRI in patients with newly diagnosed breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 992-1001.	6.4	32
8	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. Journal of Nuclear Medicine, 2022, 63, 76-80.	5.0	20
9	Hybrid total-body pet scannersâ€"current status and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 445-459.	6.4	42
10	Imaging the Inflammatory Response in Checkpoint Inhibition Myocarditis. Journal of Nuclear Medicine, 2022, 63, 14-16.	5.0	4
11	Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice. Journal of Nuclear Medicine, 2022, 63, 1357-1363.	5.0	1
12	Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1386-1406.	6.4	24
13	Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer. Radiotherapy and Oncology, 2022, 168, 37-39.	0.6	4
14	Virtual Biopsy: Just an AI Software or a Medical Procedure?. Journal of Nuclear Medicine, 2022, 63, 511-513.	5.0	11
15	Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma. Cancer Imaging, 2022, 22, 11.	2.8	2
16	Free-breathing 3D Stack of Stars GRE (StarVIBE) sequence for detecting pulmonary nodules in 18F-FDG PET/MRI. EJNMMI Physics, 2022, 9, 11.	2.7	2
17	A Role of PET/MR in Breast Cancer?. Seminars in Nuclear Medicine, 2022, 52, 611-618.	4.6	10
18	Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers. Molecular Imaging and Biology, 2022, , 1.	2.6	2

#	Article	IF	Citations
19	Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology. International Journal of Molecular Sciences, 2022, 23, 3802.	4.1	3
20	Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy â€“ A German position paper from Surgery and Nuclear Medicine. Nuklearmedizin - NuclearMedicine, 2022, 61, .	0.7	7
21	Multiparametric 18F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers, 2022, 14, 1727.	3.7	20
22	A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3340-3352.	6.4	30
23	Clinical Use of PET/MR in Oncology: An Update. Seminars in Nuclear Medicine, 2022, 52, 356-364.	4.6	18
24	First experiences with dynamic renal [68Ga]Ga-DOTAÂPET/CT: a comparison to renal scintigraphy and compartmental modelling to non-invasively estimate the glomerular filtration rate. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3373-3386.	6.4	5
25	Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2300-2309.	6.4	20
26	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. Journal of Nuclear Medicine, 2022, , jnumed.121.263072.	5.0	28
27	Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center. Journal of Nuclear Medicine, 2022, 63, 1836-1843.	5.0	5
28	Effects of Antiâ€“Tumor Necrosis Factor Therapy on Osteoblastic Activity at Sites of Inflammatory and Structural Lesions in Radiographic Axial Spondyloarthritis: A Prospective ‹scp›Proofâ€ofâ€Concept‹/scp› Study Using Positron Emission Tomography/Magnetic Resonance Imaging of the Sacroiliac Joints and Spine. Arthritis and Rheumatology, 2022, 74, 1497-1505.	5.6	6
29	Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study. Clinical Cancer Research, 2022, 28, 4194-4202.	7.0	28
30	A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma. Seminars in Nuclear Medicine, 2022, 52, 816-823.	4.6	5
31	EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. European Urology Oncology, 2022, 5, 530-536.	5.4	20
32	Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4271-4281.	6.4	38
33	Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. Clinical Cancer Research, 2022, 28, 4346-4353.	7.0	45
34	Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. Immunotherapy, 2022, 14, 927-944.	2.0	7
35	Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma. Journal of Nuclear Medicine, 2021, 62, 191-194.	5.0	10
36	Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 469-476.	6.4	119

#	Article	IF	Citations
37	Evaluation of ¹⁸F-FDG PET and DWI Datasets for Predicting Therapy Response of Soft-Tissue Sarcomas Under Neoadjuvant Isolated Limb Perfusion. Journal of Nuclear Medicine, 2021, 62, 348-353.	5.0	9
38	Correlation of the apparent diffusion coefficient (ADC) and standardized uptake values (SUV) with overall survival in patients with primary non-small cell lung cancer (NSCLC) using 18F-FDG PET/MRI. European Journal of Radiology, 2021, 134, 109422.	2.6	4
39	EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 67-72.	6.4	62
40	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 501-508.	6.4	30
41	PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1200-1210.	6.4	72
42	Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. Journal of Nuclear Medicine, 2021, 62, 675-678.	5.0	16
43	⁶⁸Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. Journal of Nuclear Medicine, 2021, 62, 1235-1241.	5.0	39
44	Evaluation of 18F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision. BMC Cancer, 2021, 21, 62.	2.6	16
45	Machine learning-based differentiation between multiple sclerosis and glioma WHO IIÂ°-IVÂ° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography. Journal of Neuro-Oncology, 2021, 152, 325-332.	2.9	11
46	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1522-1537.	6.4	6
47	Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancer. EJNMMI Physics, 2021, 8, 14.	2.7	11
48	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1626-1638.	6.4	188
49	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. European Journal of Cancer, 2021, 144, 200-214.	2.8	12
50	Imaging Inflammation with Positron Emission Tomography. Biomedicines, 2021, 9, 212.	3.2	24
51	Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2894-2903.	6.4	11
52	EANM Focus 3: The International Conference on Molecular Imaging and Theranostics in Neuroendocrine Tumoursâ€"the consensus in a nutshell. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1276-1277.	6.4	4
53	Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision. EJNMMI Research, 2021, 11, 21.	2.5	10
54	Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. European Urology Oncology, 2021, 4, 714-730.	5.4	16

#	Article	IF	Citations
55	Prostate-specific Membrane Antigenâ€“based Imaging of Castration-resistant Prostate Cancer. European Urology Focus, 2021, 7, 279-287.	3.1	17
56	Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4028-4041.	6.4	24
57	Just another â€œClever Hansâ€? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3141-3150.	6.4	23
58	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. European Journal of Cancer, 2021, 146, 56-73.	2.8	120
59	Predictive Factors for RAI-Refractory Disease and Short Overall Survival in PDTC. Cancers, 2021, 13, 1728.	3.7	7
60	Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. European Radiology, 2021, 31, 8714-8724.	4.5	43
61	Theranostics in Boron Neutron Capture Therapy. Life, 2021, 11, 330.	2.4	32
62	Nuclear Medicine beyond VISION. Journal of Nuclear Medicine, 2021, 62, jnumed.121.262441.	5.0	5
63	FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3550-3559.	6.4	21
64	Insights into immunometabolism: A dataset correlating the 18FDG PET/CT maximum standard uptake value of the primary tumor with the CCL18 serum level in non-small cell lung cancer. Data in Brief, 2021, 35, 106859.	1.0	3
65	Correlation between contrast enhancement, standardized uptake value (SUV), and diffusion restriction (ADC) with tumor grading in patients with therapy-naive neuroendocrine neoplasms using hybrid 68Ga-DOTATOC PET/MRI. European Journal of Radiology, 2021, 137, 109588.	2.6	5
66	2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2668-2669.	6.4	2
67	Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Nonâ€“Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy. Journal of Nuclear Medicine, 2021, 62, 1684-1691.	5.0	5
68	Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. BMC Cancer, 2021, 21, 512.	2.6	14
69	FDG-PET avidity as a prognostic biomarker for overall survival in renal cell carcinoma.. Journal of Clinical Oncology, 2021, 39, e16564-e16564.	1.6	0
70	Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET): An explorative, multicenter study.. Journal of Clinical Oncology, 2021, 39, 5066-5066.	1.6	2
71	Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. Nuclear Medicine and Biology, 2021, 96-97, 101-111.	0.6	10
72	PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease. Journal of Nuclear Medicine, 2021, 62, 1747-1750.	5.0	16

#	Article	IF	Citations
73	Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ¹⁷⁷Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. Journal of Nuclear Medicine, 2021, 62, 1440-1446.	5.0	37
74	Evaluation of the Predictive Potential of 18F-FDG PET and DWI Data Sets for Relevant Prognostic Parameters of Primary Soft-Tissue Sarcomas. Cancers, 2021, 13, 2753.	3.7	7
75	Changes in the global impact of COVID-19 on nuclear medicine departments during 2020: an international follow-up survey. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4318-4330.	6.4	13
76	Comparison of pre- and post-contrast-enhanced attenuation correction using a CAIPI-accelerated T1-weighted Dixon 3D-VIBE sequence in 68Ga-DOTATOC PET/MRI. European Journal of Radiology, 2021, 139, 109691.	2.6	4
77	Multiparametric Integrated 18F-FDG PET/MRI-Based Radiomics for Breast Cancer Phenotyping and Tumor Decoding. Cancers, 2021, 13, 2928.	3.7	34
78	N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard. EJNMMI Research, 2021, 11, 68.	2.5	2
79	The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far. Nuclear Medicine and Biology, 2021, 98-99, 30-39.	0.6	40
80	Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 7431.	4.1	25
81	Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). Journal of Nuclear Medicine, 2021, 62, 1447-1456.	5.0	14
82	Thymic hyperplasia after mRNA based Covid-19 vaccination. Radiology Case Reports, 2021, 16, 3744-3745.	0.6	8
83	Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncology, The, 2021, 22, 1115-1125.	10.7	120
84	Initial clinical experience with ⁹⁰Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. Journal of Nuclear Medicine, 2021, , jnumed.121.262468.	5.0	64
85	Repeatability of 68Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume. Journal of Nuclear Medicine, 2021, , jnumed.121.262528.	5.0	6
86	Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. JAMA Oncology, 2021, 7, 1635.	7.1	138
87	Lutetium-177â€“PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2021, 385, 1091-1103.	27.0	1,042
88	Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition. Radiation Oncology, 2021, 16, 176.	2.7	6
89	Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. European Urology, 2021, 80, 520-521.	1.9	2
90	FDG-PET/CT Variants and Pitfalls in Haematological Malignancies. Seminars in Nuclear Medicine, 2021, 51, 554-571.	4.6	9

#	Article	IF	Citations
91	Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imagingâ€"utilization of a short-pass filter to reduce technical pitfalls. Translational Andrology and Urology, 2021, 10, 3972-3985.	1.4	4
92	PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study. Journal of Nuclear Medicine, 2021, 62, 88-91.	5.0	21
93	Nuclear medicine theranostics comes of age. Lancet Oncology, The, 2021, 22, 1497-1498.	10.7	11
94	Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. Frontiers in Oncology, 2021, 11, 772530.	2.8	14
95	In Vivo Targeting of CXCR4â€"New Horizons. Cancers, 2021, 13, 5920.	3.7	23
96	Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results. PLoS ONE, 2021, 16, e0260804.	2.5	11
97	Atypical bilateral ventilation/perfusion mismatches in an asymptomatic patient suffering from metastatic thyroid cancer. European Journal of Hybrid Imaging, 2021, 5, 25.	1.5	1
98	18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 768-777.	6.4	11
99	Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 9-15.	6.4	67
100	Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria. Journal of Nuclear Medicine, 2020, 61, 678-682.	5.0	81
101	Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. Journal of Nuclear Medicine, 2020, 61, 1037-1042.	5.0	19
102	PET/MRI Versus PET/CT for Whole-Body Staging: Results from a Single-Center Observational Study on 1,003 Sequential Examinations. Journal of Nuclear Medicine, 2020, 61, 1131-1136.	5.0	57
103	Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation. Lung Cancer, 2020, 139, 165-168.	2.0	4
104	Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization. Journal of Clinical Medicine, 2020, 9, 56.	2.4	35
105	Joint Imaging Platform for Federated Clinical Data Analytics. JCO Clinical Cancer Informatics, 2020, 4, 1027-1038.	2.1	39
106	Global Impact of COVID-19 on Nuclear Medicine Departments: An International Survey in April 2020. Journal of Nuclear Medicine, 2020, 61, 1278-1283.	5.0	51
107	Is there a connection between immunohistochemical markers and grading of lung cancer with apparent diffusion coefficient (ADC) and standardised uptake values (SUV) of hybrid 18Fâ€FDGâ€PET/MRI?. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 779-786.	1.8	0
108	18F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET?. Journal of Clinical Medicine, 2020, 9, 3163.	2.4	9

#	Article	IF	Citations
109	Diagnostic Performance of Simultaneous [18F]-FDG PET/MR for Assessing Endoscopically Active Inflammation in Patients with Ulcerative Colitis: A Prospective Study. Journal of Clinical Medicine, 2020, 9, 2474.	2.4	5
110	Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncology, The, 2020, 21, e431-e443.	10.7	51
111	Impact of ⁶⁸Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. Journal of Nuclear Medicine, 2020, 61, 1793-1799.	5.0	74
112	Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI. Radiology, 2020, 296, 143-151.	7.3	28
113	Nuclear medicine and molecular imaging advances in the 21st century. British Journal of Radiology, 2020, 93, 20200095.	2.2	42
114	Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. European Urology, 2020, 78, 148-154.	1.9	39
115	Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. European Urology, 2020, 78, 470-471.	1.9	0
116	Impact of 18F-FDG PET/MR on therapeutic management in high risk primary breast cancer patients â€“ A prospective evaluation of staging algorithms. European Journal of Radiology, 2020, 128, 108975.	2.6	18
117	Molecular Imaging and Therapy of Colorectal and Anal Cancer. Seminars in Nuclear Medicine, 2020, 50, 465-470.	4.6	6
118	Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors. Nuclear Medicine Communications, 2020, 41, 363-369.	1.1	16
119	Evaluation of improved attenuation correction in whole-body PET/MR on patients with bone metastasis using various radiotracers. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2269-2279.	6.4	9
120	Comparison of ¹⁸F-FDG PET-MR and fecal biomarkers in the assessment of disease activity in patients with ulcerative colitis. British Journal of Radiology, 2020, 93, 20200167.	2.2	10
121	Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by [18F]FDG PET/CT and [18F]FDG PET/MRI. Nuclear Medicine and Molecular Imaging, 2020, 54, 183-191.	1.0	7
122	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. Journal of Nuclear Medicine, 2020, 61, 1094-1095.	5.0	6
123	Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving ¹⁷⁷Lu-PSMA-617 Radioligand Therapy. Theranostics, 2020, 10, 7812-7820.	10.0	75
124	Comparison of acceptance of PET/MR enterography and ileocolonoscopy in patients with inflammatory bowel diseases. Clinical Imaging, 2020, 64, 11-17.	1.5	5
125	Cardiac PET/MRI: Current Clinical Status and Future Perspectives. Seminars in Nuclear Medicine, 2020, 50, 260-269.	4.6	12
126	18F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis. PLoS ONE, 2020, 15, e0227906.	2.5	29

#	Article	IF	Citations
127	Radiomics Analysis of Multiparametric PET/MRI for N- and M-Staging in Patients with Primary Cervical Cancer. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 192, 754-763.	1.3	13
128	In vivo biodistribution of calcium phosphate nanoparticles after intravascular, intramuscular, intratumoral, and soft tissue administration in mice investigated by small animal PET/CT. Acta Biomaterialia, 2020, 109, 244-253.	8.3	37
129	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. Journal of Nuclear Medicine, 2020, 61, 552-562.	5.0	10
130	Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences. Journal of Nuclear Medicine, 2020, 61, 626-629.	5.0	65
131	Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2816-2825.	6.4	23
132	Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient. BMC Cancer, 2020, 20, 326.	2.6	38
133	Impact of COVID-19 on Nuclear Medicine in Germany, Austria andÂSwitzerland: An International Survey in April 2020. Nuklearmedizin - NuclearMedicine, 2020, 59, 294-299.	0.7	22
134	â€œCOVID-19 Pandemic as stimulator to Re-Establish Nuclear Medicine as Clinical Specialtyâ€•based on a report of Prof. Dr. Ignasi Carrio. Nuklearmedizin - NuclearMedicine, 2020, 59, 405-408.	0.7	3
135	Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 437-445.	6.4	44
136	EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2536-2544.	6.4	265
137	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 7448-7454.	7.0	190
138	Driving the Future of Nuclear Medicine. Journal of Nuclear Medicine, 2019, 60, 1S-2S.	5.0	9
139	Molecular Imaging for Primary Staging of Prostate Cancer. Seminars in Nuclear Medicine, 2019, 49, 271-279.	4.6	9
140	Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. JAMA Oncology, 2019, 5, 856.	7.1	493
141	¹⁸F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas. Journal of Nuclear Medicine, 2019, 60, 1537-1542.	5.0	19
142	Novel Structured Reporting Systems for Theranostic Radiotracers. Journal of Nuclear Medicine, 2019, 60, 577-584.	5.0	24
143	Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1439-1447.	6.4	8
144	Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. European Urology Oncology, 2019, 2, 152-162.	5.4	29

#	Article	IF	Citations
145	Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus. Journal of Nuclear Medicine, 2019, 60, 7-8.	5.0	10
146	Assessment of Ileocolonic Inflammation in Crohnâ€™s Disease: Which Surrogate Marker Is Betterâ€”MaRIA, Clermont, or PET/MR Index? Initial Results of a Feasibility Trial. Journal of Nuclear Medicine, 2019, 60, 851-857.	5.0	22
147	The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 235-252.	0.7	20
148	Current and Emerging Applications. , 2018, , 1-8.		0
149	[18F]FDG PET/MR enterography for the assessment of inflammatory activity in Crohnâ€™s disease: comparison of different MRI and PET parameters. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1382-1393.	6.4	19
150	Potential Impact of ⁶⁸Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1714-1721.	5.0	81
151	Comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. Journal of Nuclear Medicine, 2018, 59, 789-794.	5.0	68
152	Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. Nuclear Medicine and Biology, 2018, 61, 36-44.	0.6	26
153	Detection Threshold and Reproducibility of ⁶⁸Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1392-1397.	5.0	21
154	MET Expression in Advanced Nonâ€“Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. Clinical Lung Cancer, 2018, 19, e441-e463.	2.6	61
155	Simultaneous multiparametric PET/MRI for the assessment of therapeutic response to chemotherapy or concurrent chemoradiotherapy of cervical cancer patients: Preliminary results. Clinical Imaging, 2018, 49, 163-168.	1.5	29
156	Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activities. Nuclear Medicine Communications, 2018, 39, 457-464.	1.1	5
157	Dualâ€phase hybrid ¹⁸Fâ€Fluoride Positron emission tomography/<scp>MRI</scp> in ankylosing spondylitis: Investigating the link between <scp>MRI</scp> bone changes, regional hyperaemia and increased osteoblastic activity. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 313-319.	1.8	18
158	Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. Journal of Nuclear Medicine, 2018, 59, 66-74.	5.0	228
159	Comparison of 18F-FDG PET/MRI and MRI for pre-therapeutic tumor staging of patients with primary cancer of the uterine cervix. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 67-76.	6.4	49
160	Comparison of 18Fâ€“FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 622-629.	6.4	41
161	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. Journal of Nuclear Medicine, 2018, 59, 469-478.	5.0	372
162	⁶⁸Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. Journal of Nuclear Medicine, 2018, 59, 230-237.	5.0	226

#	Article	IF	Citations
163	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Research, 2018, 8, 96.	2.5	58
164	Quantitative performance of 124I PET/MR of neck lesions in thyroid cancer patients using 124I PET/CT as reference. EJNMMI Physics, 2018, 5, 13.	2.7	14
165	Local and whole-body staging in patients with primary breast cancer: a comparison of one-step to two-step staging utilizing 18F-FDG-PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2328-2337.	6.4	28
166	Comparison of the clinical performance of upper abdominal PET/DCE-MRI with and without concurrent respiratory motion correction (MoCo). European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2147-2154.	6.4	28
167	A PET for All Seasons: 18 F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis?. European Urology, 2017, 71, 934-935.	1.9	0
168	The Impact of Somatostatin Receptorâ€“Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. Journal of Nuclear Medicine, 2017, 58, 756-761.	5.0	158
169	68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1014-1024.	6.4	589
170	18F-FDG PET/MRI in patients suffering from lymphoma: how much MRI information is really needed?. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1005-1013.	6.4	16
171	⁶⁸Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. Journal of Nuclear Medicine, 2017, 58, 1617-1623.	5.0	111
172	Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT. European Radiology, 2017, 27, 4091-4099.	4.5	66
173	Integrated 18Fâ€“FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1823-1831.	6.4	43
174	Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. Journal of Nuclear Medicine, 2017, 58, 1793-1796.	5.0	24
175	Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1742-1750.	6.4	22
176	Establishing ¹⁷⁷Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1786-1792.	5.0	35
177	Current Concepts in ⁶⁸Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies. Journal of Nuclear Medicine, 2017, 58, 1718-1726.	5.0	76
178	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 67S-76S.	5.0	163
179	CXCR4 Ligands: The Next Big Hit?. Journal of Nuclear Medicine, 2017, 58, 77S-82S.	5.0	118
180	Theranostic Concepts: More Than Just a Fashion Trendâ€”Introduction and Overview. Journal of Nuclear Medicine, 2017, 58, 1S-2S.	5.0	36

#	Article	IF	Citations
181	¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography May Exclude Malignancy in Sonographically Suspicious and Scintigraphically Hypofunctional Thyroid Nodules and Reduce Unnecessary Thyroid Surgeries. Thyroid, 2017, 27, 1300-1306.	4.5	7
182	PSMA Ligands for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1545-1552.	5.0	165
183	PSMA ligands in prostate cancer â€“ Probe optimization and theranostic applications. Methods, 2017, 130, 42-50.	3.8	43
184	¹⁷⁷Lu-PSMA Radioligand Therapy for Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1196-1200.	5.0	159
185	Human Biodistribution and Radiation Dosimetry of ¹⁸F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway. Journal of Nuclear Medicine, 2017, 58, 374-378.	5.0	17
186	⁶⁸Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients. Journal of Nuclear Medicine, 2017, 58, 307-311.	5.0	27
187	Radiation Dosimetry for¹⁷⁷Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. Journal of Nuclear Medicine, 2017, 58, 445-450.	5.0	144
188	[⁶⁸Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [¹⁸F]FDG and laboratory values. Theranostics, 2017, 7, 205-212.	10.0	138
189	18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine. PLoS ONE, 2017, 12, e0180349.	2.5	33
190	Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT. PLoS ONE, 2017, 12, e0172553.	2.5	34
191	Diagnostic accuracy of 18Fâ€“FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma. BMC Cancer, 2017, 17, 887.	2.6	16
192	⁶⁸Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma. Theranostics, 2016, 6, 428-434.	10.0	91
193	Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Research, 2016, 6, 78.	2.5	78
194	Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1177-1188.	3.1	38
195	Evaluation of Prostate Cancer with ¹¹C-Acetate PET/CT. Journal of Nuclear Medicine, 2016, 57, 30S-37S.	5.0	36
196	68 Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Blockâ€”Early or Too Early to Draw Conclusions?. European Urology, 2016, 70, 938-940.	1.9	13
197	Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites. Journal of Nuclear Medicine, 2016, 57, 2016-2021.	5.0	35
198	Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2122-2130.	6.4	42

#	Article	IF	Citations
199	PET imaging in prostate cancer, future trends: PSMA ligands. Clinical and Translational Imaging, 2016, 4, 467-472.	2.1	6
200	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. Journal of Nuclear Medicine, 2016, 57, 248-251.	5.0	201
201	¹⁸F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients. Journal of Nuclear Medicine, 2016, 57, 420-430.	5.0	156
202	PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 55-69.	6.4	200
203	Impact of ⁶⁸Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective. Journal of Nuclear Medicine, 2015, 56, 70-75.	5.0	60
204	Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe ⁶⁸Ga-Pentixafor. Journal of Nuclear Medicine, 2015, 56, 410-416.	5.0	108
205	Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. Journal of Nuclear Medicine, 2015, 56, 855-861.	5.0	122
206	PET Tracers in Musculoskeletal Disease beyond FDG. Seminars in Musculoskeletal Radiology, 2014, 18, 123-132.	0.7	13
207	Perceived Misinterpretation Rates in Oncologic ¹⁸F-FDG PET/CT Studies: A Survey of Referring Physicians. Journal of Nuclear Medicine, 2014, 55, 1925-1929.	5.0	12
208	Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 Patients. Journal of Nuclear Medicine, 2014, 55, 59S-62S.	5.0	45
209	Comparison of the Amino Acid Tracers ¹⁸F-FET and ¹⁸F-DOPA in High-Grade Glioma Patients. Journal of Nuclear Medicine, 2014, 55, 1611-1616.	5.0	90
210	PET/CT in Oncology: Current Status and Perspectives. Current Radiology Reports, 2013, 1, 177-190.	1.4	77
211	Evaluation of the Genisys4, a Bench-Top Preclinical PET Scanner. Journal of Nuclear Medicine, 2013, 54, 1162-1167.	5.0	32
212	¹⁸F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib. Journal of Nuclear Medicine, 2011, 52, 1684-1689.	5.0	94
213	Comparison of Different SUV-Based Methods for Response Prediction to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer by FDG-PET and MRI. Molecular Imaging and Biology, 2011, 13, 1011-1019.	2.6	27
214	The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. International Journal of Colorectal Disease, 2009, 24, 191-200.	2.2	79
215	Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 170-183.	17.8	18
216	Therapy Monitoring with Fluorine-18 FDG-PET and Fluorine-18 FDG-PET/CT. PET Clinics, 2008, 3, 217-226.	3.0	0